Delivery Order SPE2DB24D2205-SPE2DB25FEFGQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $74,493.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (quantity: 30s) on August 8, 2025, with completion targeted for August 11, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $87,792.14. This firm fixed-price delivery order, awarded on July 23, 2025, represents a non-set-aside competitive award with an ultimate completion date of July 24, 2025. The pharmaceutical products will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and...
- The Defense Logistics Agency awarded a Firm Fixed Price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $3,622.62, with an ultimate completion date of July 30, 2025. This is a non-set-aside, competitively awarded contract executed on July 29, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.99...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $5,846.07 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 21, 2025, with a completion date of August 22, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, to be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a delivery order valued at $3,111.66 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside delivery order executed by the prime contractor, whose corporate office is located in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for RINVOQ ER 15 mg tablets (30-unit bottles) under a firm fixed-price contract valued at $10,362.56. This is a non-set-aside competitive award with an ultimate completion date of July 30, 2025. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a $3,173.42 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This non-competitive, non-set-aside contract represents a routine pharmaceutical procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The delivery location is AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFGQDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract valued at approximately $12.0K. This award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and a major pharmaceutical distribution center supporting federal medical procurement. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (SPE2DX) with DLA valued at $999.9M through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical vendor to federal medical supply chains, AmerisourceBergen supplies a broad range of medications and medical commodities to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. RINVOQ ER (upadacitinib extended-release), a JAK inhibitor used in rheumatology and gastroenterology, represents the type of specialty pharmaceutical product commonly delivered through this prime vendor arrangement to support military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.0k | 7/23/25 |